The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The c-MET oncoprotein is a key driver of cancer progression in various tumors.
• c-MET is regulated and degraded through complex cellular mechanisms including lysosomal and proteasomal pathways.
• Targeting c-MET degradation presents a promising therapeutic strategy.

Purpose of the Study:

• To investigate novel compounds for their ability to target and down-regulate the c-MET oncoprotein.
• To elucidate the mechanisms by which these compounds affect c-MET levels and activity.

Main Methods:

• Evaluation of anti-tumor activity of novel di-2-pyridylketone thiosemicarbazones.
• Analysis of c-MET down-regulation mechanisms, including intracellular iron binding, MET mRNA regulation, lysosomal processing, and metalloprotease-mediated cleavage.

Main Results:

• Novel di-2-pyridylketone thiosemicarbazones exhibit significant anti-tumor effects.
• These compounds effectively down-regulate c-MET through multiple mechanisms.
• Observed mechanisms include intracellular iron binding, reduced MET mRNA, enhanced lysosomal degradation, and increased metalloprotease cleavage.

Conclusions:

• Understanding c-MET regulation and degradation is crucial for developing effective cancer therapeutics.
• Novel thiosemicarbazone compounds demonstrate potential as anti-cancer agents by targeting c-MET degradation pathways.